Salvianolic acid a inhibits neuroinflammation and ameliorates Alzheimer's disease pathology via the p38 MAPK/NF-κB pathway based on network pharmacology and experimental validation
International Immunopharmacology · 2026-06 · 178 · 116594
DOI: 10.1016/j.intimp.2026.116594 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2026-06. Verfasst von Shifeng Xiao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Shenzhen Key Laboratory of Marine Biotechnology and Ecology, College of Life Sciences and Oceanography, Shenzhen University, Shenzhen 518060, China; …. Hauptthemen laut MEDLINE: Alzheimer Disease, Anti-Inflammatory Agents, Caffeic Acids, Lactates. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: Shenzhen Science and Technology Innovation Commission, National Natural Science Foundation of China, Basic and Applied Basic Research Foundation of Guangdong Province.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease (AD) represents the most prevalent form of neurodegenerative disorder, characterized by progressive cognitive impairments and a scarcity of effective treatments. Salvianolic acid A (SalA), a natural phytochemical endowed with antioxidative, antiapoptotic, and anti-inflammatory properties, emerges as a promising therapeutic candidate for AD. This study explored the therapeutic efficacy and underlying mechanisms of SalA in mitigating AD-related pathologies. Through integrative network pharmacology, molecular docking, and pathway enrichment analysis, p38 MAPK and NF-κB were identified as potential targets of SalA in the context of AD. SalA treatment inhibited the activation of the p38 MAPK/NF-κB pathway via targeting p38 MAPK, leading to decreased levels of IL-1α and IL-1β in lipopolysaccharide (LPS)-stimulated HMC3 cells. In an in vivo 3 × Tg-AD mouse model, SalA administration ameliorated cognitive decline associated with AD, decreased tau protein hyperphosphorylation in the hippocampus and cortex, and reduced amyloid-β (Aβ) accumulation and β-site amyloid precursor protein cleaving enzyme 1 (BACE1) levels. Furthermore, SalA attenuated the activation of the p38 MAPK/NF-κB pathway and the expression of related inflammatory cytokines in the brains of 3 × Tg-AD mice. In conclusion, this study elucidates the promising ameliorative effects of SalA on improving AD pathology, primarily through the modulation of the p38 MAPK/NF-κB signaling pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shenzhen Key Laboratory of Marine Biotechnology and Ecology, College of Life Sciences and Oceanography, Shenzhen University, Shenzhen 518060, China; Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Res…
- Shenzhen Key Laboratory of Marine Biotechnology and Ecology, College of Life Sciences and Oceanography, Shenzhen University, Shenzhen 518060, China.
Förderung
- Shenzhen Science and Technology Innovation Commission
- National Natural Science Foundation of China
- Basic and Applied Basic Research Foundation of Guangdong Province
- Shenzhen-Hong Kong Institute of Brain Science
Zitieren
APA
Xiao, S., Han, Y., Yan, J., Wu, L., Lin, H., Yuan, C., Song, C., & Ye, J. (2026). Salvianolic acid a inhibits neuroinflammation and ameliorates Alzheimer's disease pathology via the p38 MAPK/NF-κB pathway based on network pharmacology and experimental validation. International Immunopharmacology, 178, 116594. https://doi.org/10.1016/j.intimp.2026.116594
Vancouver
Xiao S, Han Y, Yan J, Wu L, Lin H, Yuan C, et al. Salvianolic acid a inhibits neuroinflammation and ameliorates Alzheimer's disease pathology via the p38 MAPK/NF-κB pathway based on network pharmacology and experimental validation. International Immunopharmacology. 2026;178:116594. doi:10.1016/j.intimp.2026.116594
BibTeX
@article{Xiao2026,
author = {Xiao, Shifeng and Han, Yuping and Yan, Ji and Wu, Lijuan and Lin, Haitong and Yuan, Cuiyi and Song, Changjie and Ye, Jinwang},
title = {Salvianolic acid a inhibits neuroinflammation and ameliorates Alzheimer's disease pathology via the p38 MAPK/NF-κB pathway based on network pharmacology and experimental validation},
journal = {International Immunopharmacology},
year = {2026},
volume = {178},
pages = {116594},
doi = {10.1016/j.intimp.2026.116594}
}
EUVIMED